Cellvie (Group)

https://www.cellvie.bio

Founded in the US and headquartered close to Zürich, Switzerland, cellvie is developing medicines from cells, leveraging the therapeutic potential of mitochondria. The company was founded by Drs. McCully, Schueller, del Nido and Emani in 2018. Dr. McCully pioneered the approach of mitochondria augmentation and replacement at Harvard Medical School and the team has now set out to bring it about as a new treatment modality in ischemia-reperfusion injury, aging, and beyond. *

	Start	2018-01-01 established
	Industry	Therapeutic Mitochondria Transfer (TMT)
	Person	Schüller, Alexander (Cellvie 202101 CEO + Co-Founder)

	Region	Zürich ZH
	Country	Switzerland
	City	n. a. Zürich (close to)
		Address record changed: 2021-01-28

Basic data	Employees	n. a.

		* Document for »About Section«: Cellvie Inc.. (1/25/21). "Press Release: Harvard Spin-off Cellvie Closes $5M Seed Round in Pursuit of a New Treatment Modality – Therapeutic Mitochondria Transfer". Zurich & Houston, TX.

		Record changed: 2025-03-16

Picture Berlin Partner Top News Robotics Network Berlin-Brandenburg 650x200px

More documents for Cellvie (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]